NASDAQ:DRRX - DURECT Stock Price, Forecast & News

DURECT's stock was trading at $1.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DRRX shares have decreased by 5.5% and is now trading at $1.56. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DURECT.

DURECT is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for DURECT.

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings results on Tuesday, March, 3rd. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The specialty pharmaceutical company had revenue of $10.69 million for the quarter, compared to analyst estimates of $12.55 million. DURECT had a negative return on equity of 100.24% and a negative net margin of 69.61%. View DURECT's earnings history.

5 brokers have issued twelve-month target prices for DURECT's shares. Their forecasts range from $2.10 to $5.50. On average, they expect DURECT's share price to reach $4.40 in the next twelve months. This suggests a possible upside of 182.1% from the stock's current price. View analysts' price targets for DURECT.

News coverage about DRRX stock has trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DURECT earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutDURECT.

Some companies that are related to DURECT include Madrigal Pharmaceuticals (MDGL), Heron Therapeutics (HRTX), Zogenix (ZGNX), ZEALAND PHARMA/S (ZEAL), Amneal Pharmaceuticals (AMRX), NextCure (NXTC), Esperion Therapeutics (ESPR), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Akebia Therapeutics (AKBA), Aimmune Therapeutics (AIMT), Odonate Therapeutics (ODT), Y-mAbs Therapeutics (YMAB), Revance Therapeutics (RVNC) and Intra-Cellular Therapies (ITCI).

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Geron (GERN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Advanced Micro Devices (AMD), Immunomedics (IMMU) and Verastem (VSTM).

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

DURECT's stock is owned by many different retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.06%), Renaissance Technologies LLC (2.19%), Beirne Wealth Consulting Services LLC (0.86%), Geode Capital Management LLC (0.79%), Gagnon Securities LLC (0.61%) and Acadian Asset Management LLC (0.59%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder and Michael Arenberg. View institutional ownership trends for DURECT.

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Assenagon Asset Management S.A., Virtu Financial LLC, Gagnon Securities LLC, Cubist Systematic Strategies LLC, and Citigroup Inc.. View insider buying and selling activity for DURECT.

DRRX stock was acquired by a variety of institutional investors in the last quarter, including EAM Global Investors LLC, EAM Investors LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, Panagora Asset Management Inc., Alpine Global Management LLC, and California Public Employees Retirement System. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder, and Michael Arenberg. View insider buying and selling activity for DURECT.

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRRX stock can currently be purchased for approximately $1.56.

DURECT has a market capitalization of $305.48 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe. View additional information about DURECT.

The official website for DURECT is http://www.durect.com/.

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.